vs
Side-by-side financial comparison of Shoals Technologies Group, Inc. (SHLS) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Shoals Technologies Group, Inc. is the larger business by last-quarter revenue ($148.3M vs $129.7M, roughly 1.1× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 38.6%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 27.8%).
Shoals Technologies Group is a leading provider of electrical balance of systems solutions for renewable energy and e-mobility. It supplies connectivity components for solar projects, energy storage systems and EV charging infrastructure, serving clients across North America, Europe and Asia-Pacific.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
SHLS vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.3M | $129.7M |
| Net Profit | $8.1M | — |
| Gross Margin | 31.6% | 98.0% |
| Operating Margin | 11.7% | -25.0% |
| Net Margin | 5.5% | — |
| Revenue YoY | 38.6% | 73.4% |
| Net Profit YoY | 3.9% | — |
| EPS (diluted) | $0.05 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.3M | $129.7M | ||
| Q3 25 | $135.8M | $164.9M | ||
| Q2 25 | $110.8M | $114.4M | ||
| Q1 25 | $80.4M | $81.7M | ||
| Q4 24 | $107.0M | $74.8M | ||
| Q3 24 | $102.2M | $62.9M | ||
| Q2 24 | $99.2M | $54.1M | ||
| Q1 24 | $90.8M | $41.4M |
| Q4 25 | $8.1M | — | ||
| Q3 25 | $11.9M | $25.7M | ||
| Q2 25 | $13.9M | $-12.8M | ||
| Q1 25 | $-282.0K | $-41.2M | ||
| Q4 24 | $7.8M | — | ||
| Q3 24 | $-267.0K | $-54.8M | ||
| Q2 24 | $11.8M | $-70.4M | ||
| Q1 24 | $4.8M | $-136.1M |
| Q4 25 | 31.6% | 98.0% | ||
| Q3 25 | 37.0% | 99.0% | ||
| Q2 25 | 37.2% | 98.7% | ||
| Q1 25 | 35.0% | 94.3% | ||
| Q4 24 | 37.6% | 96.6% | ||
| Q3 24 | 24.8% | 97.4% | ||
| Q2 24 | 40.3% | 96.2% | ||
| Q1 24 | 40.2% | 96.4% |
| Q4 25 | 11.7% | -25.0% | ||
| Q3 25 | 13.7% | 15.1% | ||
| Q2 25 | 14.4% | -11.1% | ||
| Q1 25 | 5.4% | -52.2% | ||
| Q4 24 | 15.4% | -81.2% | ||
| Q3 24 | 4.4% | -89.3% | ||
| Q2 24 | 18.7% | -125.1% | ||
| Q1 24 | 12.8% | -336.5% |
| Q4 25 | 5.5% | — | ||
| Q3 25 | 8.7% | 15.6% | ||
| Q2 25 | 12.5% | -11.1% | ||
| Q1 25 | -0.4% | -50.4% | ||
| Q4 24 | 7.3% | — | ||
| Q3 24 | -0.3% | -87.1% | ||
| Q2 24 | 11.9% | -130.1% | ||
| Q1 24 | 5.3% | -328.9% |
| Q4 25 | $0.05 | $0.04 | ||
| Q3 25 | $0.07 | $0.28 | ||
| Q2 25 | $0.08 | $-0.14 | ||
| Q1 25 | $0.00 | $-0.47 | ||
| Q4 24 | $0.04 | $-0.71 | ||
| Q3 24 | $0.00 | $-0.70 | ||
| Q2 24 | $0.07 | $-0.91 | ||
| Q1 24 | $0.03 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.3M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $600.0M | $114.8M |
| Total Assets | $904.1M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.3M | $93.0M | ||
| Q3 25 | $8.6M | $110.9M | ||
| Q2 25 | $4.7M | $75.2M | ||
| Q1 25 | $35.6M | $61.9M | ||
| Q4 24 | $23.5M | $58.5M | ||
| Q3 24 | $11.1M | $36.4M | ||
| Q2 24 | $3.2M | $32.3M | ||
| Q1 24 | $15.2M | $43.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $141.8M | — | ||
| Q4 24 | $141.8M | — | ||
| Q3 24 | $141.8M | — | ||
| Q2 24 | $146.8M | — | ||
| Q1 24 | $168.8M | — |
| Q4 25 | $600.0M | $114.8M | ||
| Q3 25 | $589.6M | $73.6M | ||
| Q2 25 | $575.4M | $32.7M | ||
| Q1 25 | $558.9M | $32.8M | ||
| Q4 24 | $556.8M | $59.1M | ||
| Q3 24 | $545.2M | $-30.5M | ||
| Q2 24 | $544.6M | $15.1M | ||
| Q1 24 | $554.0M | $74.1M |
| Q4 25 | $904.1M | $605.2M | ||
| Q3 25 | $851.8M | $538.6M | ||
| Q2 25 | $795.0M | $555.3M | ||
| Q1 25 | $788.4M | $548.8M | ||
| Q4 24 | $793.1M | $594.1M | ||
| Q3 24 | $801.3M | $504.4M | ||
| Q2 24 | $788.4M | $551.1M | ||
| Q1 24 | $825.3M | $663.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.26× | — | ||
| Q2 24 | 0.27× | — | ||
| Q1 24 | 0.30× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.1M | $60.7M |
| Free Cash FlowOCF − Capex | $-11.3M | — |
| FCF MarginFCF / Revenue | -7.6% | — |
| Capex IntensityCapex / Revenue | 4.8% | — |
| Cash ConversionOCF / Net Profit | -0.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.1M | $60.7M | ||
| Q3 25 | $19.4M | $14.3M | ||
| Q2 25 | $-13.8M | $5.0M | ||
| Q1 25 | $15.6M | $-42.2M | ||
| Q4 24 | $14.0M | $-35.7M | ||
| Q3 24 | $15.7M | $-42.5M | ||
| Q2 24 | $37.8M | $-40.2M | ||
| Q1 24 | $12.9M | $-119.0M |
| Q4 25 | $-11.3M | — | ||
| Q3 25 | $9.0M | $14.2M | ||
| Q2 25 | $-26.0M | — | ||
| Q1 25 | $12.3M | — | ||
| Q4 24 | $12.5M | — | ||
| Q3 24 | $13.3M | — | ||
| Q2 24 | $35.8M | $-40.3M | ||
| Q1 24 | $10.4M | — |
| Q4 25 | -7.6% | — | ||
| Q3 25 | 6.6% | 8.6% | ||
| Q2 25 | -23.5% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | 11.6% | — | ||
| Q3 24 | 13.0% | — | ||
| Q2 24 | 36.1% | -74.5% | ||
| Q1 24 | 11.4% | — |
| Q4 25 | 4.8% | — | ||
| Q3 25 | 7.7% | 0.1% | ||
| Q2 25 | 11.0% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 2.3% | 0.0% | ||
| Q2 24 | 2.0% | 0.2% | ||
| Q1 24 | 2.7% | 0.0% |
| Q4 25 | -0.50× | — | ||
| Q3 25 | 1.63× | 0.56× | ||
| Q2 25 | -1.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.79× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.21× | — | ||
| Q1 24 | 2.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SHLS
| System Solutions | $122.0M | 82% |
| Components | $26.3M | 18% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
